{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:10:01Z","timestamp":1777039801825,"version":"3.51.4"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Development Research"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A series of ester tethered dihydroartemisinin\u20103\u2010(oxime\/thiosemicarbazide)isatin hybrids <jats:bold>7a\u2013p<\/jats:bold> were designed, synthesized, and assessed for their antiproliferative activity against MCF\u20107, MDA\u2010MB\u2010231, MCF\u20107\/ADR, and MDA\u2010MB\u2010231\/ADR breast cancer cell lines. Among them, hybrids <jats:bold>7a,f<\/jats:bold> (IC<jats:sub>50<\/jats:sub>: 1.33\u20133.84\u2009\u00b5M) showed potent activity against triple\u2010negative (MDA\u2010MB\u2010231 and MDA\u2010MB\u2010231\/ADR) breast cancer cell lines, and hybrid <jats:bold>7f<\/jats:bold> (IC<jats:sub>50<\/jats:sub>: 3.90 and 10.18\u2009\u00b5M) also demonstrated promising activity against estrogen receptor\u2010positive breast cancer cells (MCF\u20107 and MCF\u20107\/ADR), and the activity was superior to these of artemisinin, dihydroartemisinin, and ADR, revealing their potential to fight against both drug\u2010sensitive and drug\u2010resistant breast cancers. The enriched structure\u2013activity relationships may facilitate further design of more active candidates.<\/jats:p>","DOI":"10.1002\/ddr.22078","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T04:21:04Z","timestamp":1683778864000},"page":"1175-1182","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel ester tethered dihydroartemisinin\u20103\u2010(oxime\/thiosemicarbazide)isatin hybrids as potential anti\u2010breast cancer agents: Synthesis, in vitro cytotoxicity and structure\u2013activity relationship"],"prefix":"10.1002","volume":"84","author":[{"given":"Shaohuan","family":"Liu","sequence":"first","affiliation":[{"name":"West China School of Pharmacy Sichuan University Chengdu Sichuan Province China"},{"name":"School of Pharmacy Guizhou Medical University Guiyang Guizhou People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Wang","sequence":"additional","affiliation":[{"name":"West China School of Pharmacy Sichuan University Chengdu Sichuan Province China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Pharmacy Guizhou University of Traditional Chinese Medicine Guiyang Guizhou People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bowen","family":"Pan","sequence":"additional","affiliation":[{"name":"School of Pharmacy Guizhou University of Traditional Chinese Medicine Guiyang Guizhou People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linzhi","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmacy Guizhou University of Traditional Chinese Medicine Guiyang Guizhou People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijia","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Pharmacy Guizhou Medical University Guiyang Guizhou People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-1392","authenticated-orcid":false,"given":"Zhi","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Pharmacy Guizhou University of Traditional Chinese Medicine Guiyang Guizhou People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[{"name":"School of Pharmacy Guizhou Medical University Guiyang Guizhou People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.08.010"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf3543"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpmed.2019.11.009"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.50364"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.834317"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41745-019-00146-4"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112044"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.801580"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/chem.201901113"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-020-05669-z"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12207"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113199990440"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32381-3"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26247521"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2021.103639"},{"issue":"10","key":"e_1_2_7_19_1","first-page":"781","article-title":"Guidelines for clinical diagnosis and treatment of advanced breast cancer in China (2020 Edition) breast cancer expert committee of national cancer quality control center, breast cancer expert committee of China anti\u2010cancer association, cancer drug clinical research committee of China anti\u2010cancer association","volume":"42","author":"Xu B. H.","year":"2020","journal-title":"Chinese Clinical Oncology"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.722331"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.202200086"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2022.103721"}],"container-title":["Drug Development Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.22078","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T21:18:45Z","timestamp":1760390325000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/ddr.22078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1002\/ddr.22078"],"URL":"https:\/\/doi.org\/10.1002\/ddr.22078","archive":["Portico"],"relation":{},"ISSN":["0272-4391","1098-2299"],"issn-type":[{"value":"0272-4391","type":"print"},{"value":"1098-2299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,11]]},"assertion":[{"value":"2022-12-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}